A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 24 May 2019
Price : $35 *
At a glance
- Drugs Filgrastim (Primary) ; Plerixafor (Primary)
- Indications WHIM syndrome
- Focus Adverse reactions
- 21 May 2019 Planned End Date changed from 31 May 2021 to 5 Oct 2020.
- 21 May 2019 Planned primary completion date changed from 30 Nov 2020 to 5 Oct 2020.
- 20 Jul 2018 Status changed from recruiting to active, no longer recruiting.